Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our Best Content in Your Email

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

"Theralase Technologies Inc designs, develops, manufactures, markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain and also develops patented and patent pending drugs, called Photo Dynamic Compounds."

Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada 2 days ago

Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada 2 days ago

Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer

Filing Services Canada 3 days ago

Theralase Discovers Theralase(R) Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments

Filing Services Canada November 30, 2017

Theralase Increases Revenue 12% for 3Q2017 Financial Statements

Filing Services Canada November 29, 2017

Theralase Therapeutic Laser Technology Enhances Cancer Destruction

Filing Services Canada November 27, 2017

Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer

Filing Services Canada November 22, 2017

Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug

Filing Services Canada November 21, 2017

Theralase Discovers New Anti-Cancer Vaccine

Filing Services Canada November 20, 2017

IIROC Trading Resumption - TLT

Canada NewsWire November 13, 2017

IIROC Trading Halt - TLT

Canada NewsWire November 13, 2017

IIROC Trade Halt - Theralase Technologies Inc.

Newsfile November 13, 2017

Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated

Filing Services Canada November 8, 2017

Theralase Anti-Cancer Drugs Independently Reviewed

Filing Services Canada October 31, 2017

Theralase Research to be Presented at International Conference

Filing Services Canada October 30, 2017

Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays

Filing Services Canada September 25, 2017

Theralase Demonstrates 24 Month Stability of Lead Anti-Cancer Drug

Filing Services Canada September 18, 2017

Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug

Filing Services Canada September 12, 2017

Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer

Filing Services Canada September 5, 2017

Theralase Increases Revenue 14% for 2Q2017 Financial Statements

Filing Services Canada August 29, 2017
Read more ››